| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | BRD-K29086754 | CTRPv2 | pan-cancer | AAC | -0.089 | 0.3 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.053 | 0.3 |
| mRNA | BRD-A86708339 | CTRPv2 | pan-cancer | AAC | 0.059 | 0.3 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.06 | 0.3 |
| mRNA | lapatinib | UHNBreast | pan-cancer | AAC | -0.32 | 0.3 |
| mRNA | Crizotinib | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | Crizotinib | GDSC1000 | pan-cancer | AAC | -0.06 | 0.3 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.042 | 0.3 |
| mRNA | ML258 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | THZ-2-49 | GDSC1000 | pan-cancer | AAC | -0.032 | 0.3 |